

What is claimed is:

1. An isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7,

b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7,

c) a biologically-active fragment of the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, and

d) an immunogenic fragment of the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

2. A pharmaceutical composition comprising the antibody of claim 1 in conjunction with a suitable pharmaceutical carrier.

3. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 1 comprising:

a) immunizing an animal with the polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, or an antigenically-effective fragment thereof under conditions to elicit an antibody response;

b) isolating animal antibodies; and

c) screening the isolated antibodies with the polypeptide thereby identifying a polyclonal antibody binds specifically to the polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

4. An antibody produced by a method of claim 3.

5. A pharmaceutical composition comprising the antibody of claim 4 in conjunction with a suitable pharmaceutical carrier.

6. A method of making a monoclonal antibody with the specificity of the antibody of claim 1 comprising:

- a) immunizing an animal with the polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, or an antigenically-effective fragment thereof under conditions to elicit an antibody response;
- b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;
- d) culturing the hybridoma cells; and
- e) isolating from the culture monoclonal antibodies which binds specifically to the polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

7. A monoclonal antibody produced by a method of claim 6.

8. A pharmaceutical composition comprising the antibody of claim 7 in conjunction with a suitable pharmaceutical carrier.

9. The antibody of claim 1, wherein the antibody is:

- (a) a chimeric antibody;
- (b) a single chain antibody;
- (c) a Fab fragment; or
- (d) a F(ab')<sub>2</sub> fragment.

10. The antibody of claim 1, wherein the antibody is produced by screening a Fab expression library.

11. The antibody of claim 1, wherein the antibody is produced by screening a recombinant immunoglobulin library.

12. A method for detecting polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7 in a sample comprising the steps of:

- a) combining the antibody of claim 1 with a sample under conditions to allow specific binding; and
- b) detecting specific binding, wherein specific binding indicates the presence of polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7 in the sample.

5

13. A method of using an antibody to purify polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7 from a sample, the method comprising:

- a) combining the antibody of claim 1 with a sample under conditions to allow specific binding; and
- b) separating the antibody from the protein, thereby obtaining purified polypeptide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.